Background: Osimertinib is a major first-line treatment for advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). Acquired resistance remains a major clinical challenge, and factors associated with post-progression outcomes are incompletely understood. This study investigated clinical and molecular characteristics associated with post-progression survival, focusing on progression patterns, radiotherapy, and alterations detected through liquid biopsy. Methods: Data from two cohorts of patients with advanced EGFR-mutated NSCLC receiving first-line osimertinib were analyzed: the prospective REM cohort and the retrospective CHILD cohort. Clinical characteristics, treatment response, progression patterns, subsequent therapies, and molecular alterations were assessed. Available liquid biopsies were analyzed at progression. In patients undergoing tissue rebiopsy, molecular alterations and potential acquired resistance mechanisms, including MET amplification, were evaluated. Endpoints included first-line progression-free survival (PFS1), overall survival (OS), progression-free survival after first disease progression (PFS2), and post-progression overall survival (OS2). Prognostic associations were assessed using Kaplan–Meier estimates and Cox regression models. An exploratory analysis was performed in patients receiving radiotherapy at progression. Results: A total of 174 patients were included: 138 in REM and 36 in CHILD. Median PFS1 was 19.0 and 12.2 months, respectively, and median OS was 28.7 and 33.1 months. Median PFS2 was 6.8 months in both cohorts, while median OS2 was 10.0 months in REM and 17.6 months in CHILD. In the combined population, the development of new metastatic sites at progression was independently associated with shorter PFS2 (adjusted hazard ratio [aHR] 2.29; 95% confidence interval [CI] 1.41–3.70; p < 0.001) and OS2 (aHR 2.44; 95% CI 1.47–4.07; p < 0.001). Radiotherapy at progression was associated with a lower risk of death (aHR 0.58; 95% CI 0.37–0.92; p = 0.022). Among the 46 patients receiving radiotherapy, new metastatic sites remained independently associated with shorter PFS2 (aHR 3.40; 95% CI 1.59–7.27; p = 0.002) and were strongly associated with shorter OS2 (HR 6.96; 95% CI 2.61–18.5; p < 0.001). The adverse prognostic significance of this progression pattern therefore persisted in the radiotherapy subgroup. Molecular profiling at progression revealed heterogeneous genomic alterations, including MET amplification and sequence variants potentially relevant to acquired resistance and the selection of subsequent targeted therapies. Conclusions: The development of new metastatic sites at progression is an adverse prognostic factor in patients receiving first-line osimertinib, including those treated with radiotherapy. Although radiotherapy was associated with longer post-progression survival in the overall population, patients developing new metastatic sites continued to have unfavorable outcomes. Liquid biopsy provides complementary information on the molecular heterogeneity of resistance. These findings support integrating clinical progression patterns and molecular profiling into future prognostic models. Prospective validation is required before these observations can guide treatment personalization or identify patients who may benefit from early treatment intensification.
Introduzione: Osimertinib è uno dei principali trattamenti di prima linea per il carcinoma polmonare non a piccole cellule (NSCLC) avanzato EGFR-mutato. La resistenza acquisita rappresenta una rilevante sfida clinica e i fattori associati agli esiti dopo progressione restano incompletamente definiti. Lo studio ha analizzato le caratteristiche cliniche e molecolari associate alla sopravvivenza dopo progressione, con particolare attenzione ai pattern di progressione, alla radioterapia e alle alterazioni rilevate mediante biopsia liquida. Materiali e metodi: Sono stati analizzati i dati di due coorti di pazienti con NSCLC avanzato EGFR-mutato trattati con osimertinib in prima linea: REM, prospettica, e CHILD, retrospettiva. Sono state valutate caratteristiche cliniche, risposta al trattamento, pattern di progressione, strategie terapeutiche successive e alterazioni molecolari. Alla progressione sono state analizzate le biopsie liquide disponibili e, nei pazienti sottoposti a rebiopsia tissutale, le alterazioni molecolari e i possibili meccanismi di resistenza acquisita, inclusa l’amplificazione di MET. Gli endpoint comprendevano la sopravvivenza libera da progressione in prima linea (PFS1), la sopravvivenza globale (OS), la sopravvivenza libera da progressione dopo la prima progressione (PFS2) e la sopravvivenza globale dopo progressione (OS2). Le associazioni prognostiche sono state valutate mediante Kaplan–Meier e regressione di Cox. È stata inoltre condotta un’analisi esplorativa nei pazienti sottoposti a radioterapia alla progressione. Risultati: Sono stati inclusi 174 pazienti: 138 nella coorte REM e 36 nella coorte CHILD. La PFS1 mediana era rispettivamente di 19,0 e 12,2 mesi e la OS mediana di 28,7 e 33,1 mesi. La PFS2 mediana era di 6,8 mesi in entrambe le coorti, mentre la OS2 mediana era di 10,0 mesi in REM e 17,6 mesi in CHILD. Nella popolazione combinata, la comparsa di nuove sedi metastatiche alla progressione era indipendentemente associata a PFS2 più breve (hazard ratio aggiustato [aHR] 2,29; intervallo di confidenza [IC] 95% 1,41–3,70; p < 0,001) e OS2 inferiore (aHR 2,44; IC 95% 1,47–4,07; p < 0,001). La radioterapia alla progressione era associata a un minor rischio di morte (aHR 0,58; IC 95% 0,37–0,92; p = 0,022). Nei 46 pazienti sottoposti a radioterapia, la comparsa di nuove sedi metastatiche manteneva un’associazione indipendente con PFS2 più breve (aHR 3,40; IC 95% 1,59–7,27; p = 0,002) ed era fortemente associata a OS2 inferiore (HR 6,96; IC 95% 2,61–18,5; p < 0,001). Il significato prognostico sfavorevole di questo pattern di progressione persisteva quindi anche nel sottogruppo irradiato. La caratterizzazione molecolare alla progressione evidenziava alterazioni genomiche eterogenee, comprendenti amplificazione di MET e varianti di sequenza potenzialmente rilevanti per la resistenza acquisita e la scelta di successive terapie mirate. Conclusioni: La comparsa di nuove sedi metastatiche alla progressione rappresenta un fattore prognostico sfavorevole nei pazienti trattati con osimertinib in prima linea, anche dopo radioterapia. Sebbene quest’ultima fosse associata a migliore sopravvivenza dopo progressione nella popolazione complessiva, i pazienti con nuove sedi metastatiche mantenevano esiti sfavorevoli. La biopsia liquida offre informazioni complementari sull’eterogeneità molecolare della resistenza. I risultati supportano l’integrazione dei pattern clinici di progressione e della profilazione molecolare in futuri modelli prognostici. Sono necessari studi prospettici di validazione prima di utilizzare queste osservazioni per personalizzare le scelte terapeutiche o identificare i pazienti candidabili a un’intensificazione terapeutica precoce.
Clinical and molecular predictors of outcome after first-line Osimertinib in EGFR-mutated Non-small cell lung cancer
PANTE, FRANCESCA
2024/2025
Abstract
Background: Osimertinib is a major first-line treatment for advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). Acquired resistance remains a major clinical challenge, and factors associated with post-progression outcomes are incompletely understood. This study investigated clinical and molecular characteristics associated with post-progression survival, focusing on progression patterns, radiotherapy, and alterations detected through liquid biopsy. Methods: Data from two cohorts of patients with advanced EGFR-mutated NSCLC receiving first-line osimertinib were analyzed: the prospective REM cohort and the retrospective CHILD cohort. Clinical characteristics, treatment response, progression patterns, subsequent therapies, and molecular alterations were assessed. Available liquid biopsies were analyzed at progression. In patients undergoing tissue rebiopsy, molecular alterations and potential acquired resistance mechanisms, including MET amplification, were evaluated. Endpoints included first-line progression-free survival (PFS1), overall survival (OS), progression-free survival after first disease progression (PFS2), and post-progression overall survival (OS2). Prognostic associations were assessed using Kaplan–Meier estimates and Cox regression models. An exploratory analysis was performed in patients receiving radiotherapy at progression. Results: A total of 174 patients were included: 138 in REM and 36 in CHILD. Median PFS1 was 19.0 and 12.2 months, respectively, and median OS was 28.7 and 33.1 months. Median PFS2 was 6.8 months in both cohorts, while median OS2 was 10.0 months in REM and 17.6 months in CHILD. In the combined population, the development of new metastatic sites at progression was independently associated with shorter PFS2 (adjusted hazard ratio [aHR] 2.29; 95% confidence interval [CI] 1.41–3.70; p < 0.001) and OS2 (aHR 2.44; 95% CI 1.47–4.07; p < 0.001). Radiotherapy at progression was associated with a lower risk of death (aHR 0.58; 95% CI 0.37–0.92; p = 0.022). Among the 46 patients receiving radiotherapy, new metastatic sites remained independently associated with shorter PFS2 (aHR 3.40; 95% CI 1.59–7.27; p = 0.002) and were strongly associated with shorter OS2 (HR 6.96; 95% CI 2.61–18.5; p < 0.001). The adverse prognostic significance of this progression pattern therefore persisted in the radiotherapy subgroup. Molecular profiling at progression revealed heterogeneous genomic alterations, including MET amplification and sequence variants potentially relevant to acquired resistance and the selection of subsequent targeted therapies. Conclusions: The development of new metastatic sites at progression is an adverse prognostic factor in patients receiving first-line osimertinib, including those treated with radiotherapy. Although radiotherapy was associated with longer post-progression survival in the overall population, patients developing new metastatic sites continued to have unfavorable outcomes. Liquid biopsy provides complementary information on the molecular heterogeneity of resistance. These findings support integrating clinical progression patterns and molecular profiling into future prognostic models. Prospective validation is required before these observations can guide treatment personalization or identify patients who may benefit from early treatment intensification.| File | Dimensione | Formato | |
|---|---|---|---|
|
FRANCESCA _PANTE.pdf
Accesso riservato
Dimensione
5.46 MB
Formato
Adobe PDF
|
5.46 MB | Adobe PDF |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/119676